GlobeNewswire

VistaJet Records 39% EBITDA Growth With Strong First Quarter 2017 Results

Dela

VistaJet continues to gain market share across all markets

For the 13 weeks to 31 March 2017:

  • Flight revenues increased by 22% globally year-over-year.
  • EBITDA grew 39% year-over-year due to increased yields and efficiency.
  • New Program hours sold up 79% Q1 2017 against Q1 2016.
  • Program Membership accounts for majority of total hours flown in Q1 2017 at 55%.

LONDON, June 01, 2017 (GLOBE NEWSWIRE) -- VistaJet, the first and only global aviation company, has today announced yet another record quarter, again demonstrating its ability to consistently capture greater market share with its strong value proposition of asset free risk and truly global access.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/9e3d1364-eb1f-4e73-aa64-4dbcecb3cf76

The company recorded EBITDA growth of 39% year-on-year following a record Q1 sales success, and increased yields and efficiency due to its global infrastructure and a continued focus on technology.

The company's decision to grow its fleet to a total of over 70 identically branded and globally positioned aircraft continues to support its growth, and the average utilization trend was positive month-on-month from January 2017 to March 2017.

In the traditionally weakest quarter of the year for the aviation industry, VistaJet recorded a 22% growth in flight revenues year-on-year. The majority of growth came from VistaJet's Program segment, with existing customers utilizing and upsizing their contracts and new clients choosing to subscribe to multi-year agreements. Sales of new annual Program hours increased by 79% year-on-year, demonstrating the company's position as the only alternative to full or fractional aircraft ownership in the private aviation market. Program customers flew more hours in the first quarter than in any other period in VistaJet's history, accounting for 55% of total hours globally, up from 53% against the same quarter last year.

VistaJet's On Demand segment also grew year-on-year, with revenues increasing by 14% in spite of Easter falling outside of Q1 this year. Total On Demand flight hours remained steady year-on-year whilst live hours increased by a staggering 4% as the improvement in the ferry factor drove a decline in empty flight hours. Empty legs have long been a challenge for private aviation businesses, as companies with less scale and operational efficiency have to relocate their aircraft to pick up passengers. The company recently announced a 'Ferry Free World' for its Program clients.

VistaJet continues to record growth across the globe. The company increased its market share not only in the U.S. and Asia, both key target growth markets, but also in the more mature markets of Europe, Russia and CIS. VistaJet saw an increase of 15% year-on-year in flight hours in Europe, highlighting that the company continues to see significant growth potential in its established markets.

The U.S. business remains a driving factor in VistaJet's flight hour growth and prospect pipeline. Flight hours in North America increased by 54% year-on-year. The company also increased its regional customer base and the number of aircraft positioned in the area, which helped it to deliver flight hours growth of 43% also in Central and South America.

VistaJet performed strongly in Asia, and Program customers within the region accounted for 25% of total hours sold during Q1 2017. As a result of their global flying and access needs, both corporate and private individual Program customers in Asia are mainly flying outside of the region to Europe, the Middle East and North America, helping to drive an increase in global flight hours.

VistaJet will continue to grow hours and revenues on its established and leading aircraft and technology infrastructure, improving utilization, margins and the company's financial strength. VistaJet, as the leading global private aviation company, is continuing to benefit from the trends away from asset ownership and secure new customers who previously had to choose between whole aircraft, fractional ownership, and an inconsistent and inferior charter offering.

About VistaJet

VistaJet is the first and only global aviation company. On its fleet of silver and red business jets, VistaJet has flown corporations, governments and private clients to 187 countries worldwide. Founded in 2004 by Thomas Flohr, the company pioneered an innovative business model where customers pay only for the hours they fly, free of the responsibilities and asset risks linked to aircraft ownership. VistaJet's signature Program service offers customers a bespoke subscription of flight hours on its fleet of mid and long range jets, to fly them anywhere and at any time.

More VistaJet information and news at vistajet.com.

Information

Jennifer Tyler
VistaJet International
T: +44 203 617 3077
M: +44 7834 335505
jennifer.tyler@vistajet.com 

James Leviton
Finsbury
+44 207 251 3851
VistaJet@finsbury.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: VistaJet Ltd via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Stillfront Group rekryterar ansvarig för M&A19.12.2018 12:07Pressmeddelande

PRESSMEDDELANDE 19 december, 2018 Stillfront Group rekryterar ansvarig för M&A Stillfront Group, en marknadsledare inom 'free to play' online strategispel, annonserar idag att Marina Andersson har utsetts till ansvarig för M&A och kommer att ingå i koncernledningen. Marina har närmare tjugo års erfarenhet från investment banking och M&A. Hon har omfattande erfarenhet inom strategisk och finansiell rådgivning, affärsgenerering, projektledning inom förvärv och försäljningar av företag, finansiell analys, due diligence, samt företagsvärdering. Tidigare positioner inkluderar: Director, Deloitte's Corporate Finance Advisory team, Director, ICECAPITAL Securities, Associate Partner och Investment Manager, Deseven, samt M&A Analytiker på Carnegie. Marina har två magister-examen från Stockholms universitet och Russian Herzen State Pedagogical University. "Förvärv är en viktig del av Stillfronts affärsstrategi och vi är mycket glada att rekrytera Marina Andersson. Marinas breda erfarenhet och pr

Stillfront Group announces Head of M&A19.12.2018 12:07Pressmeddelande

PRESS RELEASE December 19, 2018 Stillfront Group announces Head of M&A Stillfront Group, a market leader in 'free to play' online strategy games, today announces that Marina Andersson has been appointed as Head of M&A and will be part of the Group's management team. Marina has close to 20 years track record of investment banking and M&A. She has extensive competence within strategic and financial advisory, deal generation, buy and sell side M&A project management, financial analysis, due diligence and company valuation. Former positions include: Director at Deloitte's Corporate Finance Advisory team, Director at ICECAPITAL Securities, Associate Partner and Investment Manager at Deseven, M&A Analyst at Carnegie. She holds two Master degrees from Stockholm University and Russian Herzen State Pedagogical University. "Acquisitions are a crucial part of Stillfront's business strategy and we are very pleased with the appointment of Marina Andersson. Marina's breadth of experience and profess

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum